Tuesday, October 13, 2026

Martin Schulz: "More Justice Also by a Common Tax Regime in EU"

European Parliament President Martin Schulz called for a common EU tax regime at the Portuguese Socialist Party congress on June 4, 2016. "The distribution of wealth in Europe is not fair," he said, criticizing speculators who avoid taxes on profits.

LM Salvado
LM Salvado

June 8, 2016

Martin Schulz, the European Parliament President, speech at the 21st Congress of the Portuguese Socialist Party.
Martin Schulz, the European Parliament President, delivered a speech at the 21st Congress of the Portuguese Socialist Party (PS) on June 4 in Lisbon, Portugal. Martin Schulz, the European Parliament President, speech at the 21st Congress of the Portuguese Socialist Party. The European Parliament President said on Saturday that there is a need to strengthen the fight against tax evasion and tax fraud.
"We are the richest part of the world. The single market of the European Union is the richest single market in the world. But the distribution of wealth in Europe is not fair and not just. What we need is more solidarity between the countries of the eurozone, between countries of the EU and among people in the EU."

Martin Schulz

"We're facing a situation where speculators make billions of profits and don't pay taxes for it. But when they make losses, the taxpayers have to pay for them. This is not the EU we want."

Martin Schulz

The European Commission has been proposing several initiatives to harmonize taxation across the 28 different tax regimes and increase competitiveness to attract more investment. The Common Consolidated Corporate Tax Base (CCCTB) was re-launched last year and aims to simplify the EU’s corporate tax system. The European Anti-Tax Avoidance Package is another Commission Directive of corporate taxation to enable companies to pay taxes where the profits happen.
"The fight against tax evasion and tax fraud. Closing of tax heavens is one of the main goals of social democrats. Not only in Europe, worldwide. And nobody else but we, is fighting for it."

Martin Schulz

"I just took a coffee here beside the conference hall. The owner of that coffee shop has to pay taxes here, but a worldwide acting American coffee company shop should not pay taxes. This is not just and fair. I think one of the main goals of social democrats is more justice, also by a common tax regime in the European Union."

Martin Schulz

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com